<DOC>
	<DOCNO>NCT00410501</DOCNO>
	<brief_summary>This study evaluate interaction potential indacaterol ketoconazole ( potent CYP3A inhibitor ) healthy adult subject .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic Interaction Indacaterol With Ketoconazole Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy , male female subject Indian origin age 18 45 year age ( inclusive ) In good health confirm past medical history , physical examination , electrocardiogram , laboratory test urinalysis screen baseline evaluation Female subject must either surgically sterilize least 6 month prior study participation postmenopausal ( regular menstrual bleeding least 2 year ) , use doublebarrier local contraception childbearing potential Body mass index ( BMI ) within range 18.5 27 kg/m2 weigh least 45 kg female 50 kg male Smokers ( use tobacco product previous 3 month ) . Using plan use medication affect GI ( gastrointestinal ) motility and/or perception ( prokinetics , antidiarrheal , antispasmodic , anticholinergic , antacid contain magnesium aluminum salt , erythromycin , octreotide , ondansetron 5HT3 antagonist ) . Use prescription drug within 4 week prior dose , overthecounter ( OTC ) medication ( vitamin , herbal supplement , dietary supplement ) within two ( 2 ) week prior dose . Paracetamol ( 4 g daily ) acceptable Participation clinical investigation within 4 week prior dose longer required local regulation , limitation participation base local regulation . Donation loss 400 mL blood within 8 week prior first dose longer required local regulation . Significant illness within two week prior dose . A past medical history clinically significant ECG abnormality . Significant history psychiatric disorder . History clinically significantfainting , low blood pressure standing , irregular heart beat acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat untreated ) drug allergy history atopic allergy ( asthma , urticaria , eczematous dermatitis , nasal polyp NSAID ( nonsteroidal antiinflammatory drug ) induce urticaria ) A know hypersensitivity severe adverse event indacaterol/ketoconazole drug similar study drug . History bowel obstruction , symptomatic gall bladder disease , suspect Sphincter Oddi dysfunction , abdominal adhesion . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . Any planned surgery procedure within 3 month screen . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C VDRL ( Venereal Disease Research Laboratory ) test result . History drug alcohol abuse within 6 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . Consumption alcohol within 48 hour receive medication . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Pharmacokinetics , interaction , QAB149 , indacaterol , ketoconazole , healthy subject</keyword>
</DOC>